Modelling expenses for multiple sclerosis treatment-Reference-Cited by-同舟云学术

Modelling expenses for multiple sclerosis treatment

Published:2020-06-01 Issue:3 Volume: Page:11-34
ISSN:
Container-title:Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology)
language:ru
Short-container-title:

Author:

Mokrova Anna¹^ORCID,Sologova Susanna¹^ORCID,Ignatyeva Victoria²^ORCID

Affiliation:

1. Sechenov First Moscow State Medical University Russia

2. Russian Presidential Academy of National Economy and Public Administration (RANEPA)

Abstract

Modern theory of multiple sclerosis requires substantial state expenditures which needs thorough clinical and economic implications assessment of introducing novel drugs in this disease treatment.

Publisher

PANORAMA Publishing House

Reference71 articles.

1. Ivanova E. V., Bakhtiyarova K. Z., Safronova E. V. Analysis of the structure of the primary disability due to multiple sclerosis in the city of Ufa over 2010–2016. Medikosotsial’naya ekspertiza i reabilitatsiya (Medical and Social Expert Evaluation and Rehabilitation, Russian Journal). 2017; 20 (3): 144–147. (In Russ.). DOI: http:// dx.doi.org/10.18821/1560-9537-2017-20-3-144-147.

2. Omel’yanovskij V. V., Avksen’t’eva M. V. Metodicheskie rekomendacii po provedeniyu sravnitel’noj kliniko-ekonomicheskoj ocenki lekarstvennogo preparata C. 1–20.

3. Mkrtchyan, V. & Brylev, L. & Davydova, O. & Belyanin, A. & Shpak, I. & Sergeev, A.. (2015). Pharmacoeconomic analysis of the use of first- and second-line drugs in the treatment of multiple sclerosis. Neurology, Neuropsychiatry, Psychosomatics. 7. 35–39. 10.14412/2074-2711-2015-3-35-39.

4. Abogunrin S., Hortobagyi L. Budget impact analysis of botulinum toxin a therapy for upper limb spasticity in the United Kingdom // ClinicoEconomics and Outcomes Research. 2015. (7). C. 185–193.

5. Agashivala N., Kim E. Cost-Effectiveness of Early Initiation of Fingolimod Versus Delayed Initiation After 1 Year of Intramuscular Interferon Beta-1a in Patients with Multiple Sclerosis // Clinical Therapeutics. 2012. № 7 (34). C. 1583–1590.